BernardGRVincentJLLaterrePFLaRosaSPDhainautJFLopez-RodriguezA, Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med2001; 344: 699–709.
2.
SniderRDKruseJABanderJJDunnGH. Accuracy of estimated creatinine clearance in obese patients with stable renal function in the intensive care unit. Pharmacotherapy1995; 15: 747–53.
3.
BlouinRAWarrenGW. Pharmacokinetic considerations in obesity. J Pharm Sci1999; 88: 1–7.
4.
CheymolG. Clinical pharmacokinetics of drugs in obesity — an update. Clin Pharmacokinet1993; 25: 103–14.
5.
MaciasWLDhainautJFYanSCBHelterbrandJDSegerMJohnsonG, Pharmacokinetic–pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clinical Pharm Ther2002; 72: 391–402.
